Allakos Inc. (NASDAQ:ALLK) insider Henrik S. Md Rasmussen sold 2,435 shares of the business’s stock in a transaction on Friday, June 4th. The stock was sold at an average price of $89.60, for a total value of $218,176.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Henrik S. Md Rasmussen also recently made the following trade(s):
- On Thursday, April 1st, Henrik S. Md Rasmussen sold 20,000 shares of Allakos stock. The stock was sold at an average price of $114.40, for a total value of $2,288,000.00.
- On Monday, April 5th, Henrik S. Md Rasmussen sold 20,000 shares of Allakos stock. The stock was sold at an average price of $113.06, for a total value of $2,261,200.00.
Shares of NASDAQ:ALLK traded down $1.25 during midday trading on Friday, reaching $89.62. 344,037 shares of the company traded hands, compared to its average volume of 242,296. Allakos Inc. has a 12 month low of $64.22 and a 12 month high of $157.98. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of -25.17 and a beta of 0.91. The business’s fifty day moving average price is $104.00.
Allakos (NASDAQ:ALLK) last released its quarterly earnings data on Sunday, May 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.18). As a group, equities research analysts forecast that Allakos Inc. will post -4.46 EPS for the current year.
Several large investors have recently added to or reduced their stakes in ALLK. E Fund Management Co. Ltd. bought a new stake in shares of Allakos during the 1st quarter valued at $128,000. Nisa Investment Advisors LLC grew its position in Allakos by 11.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 985 shares of the company’s stock worth $138,000 after buying an additional 100 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in Allakos during the first quarter worth about $142,000. Penserra Capital Management LLC grew its position in Allakos by 190.9% during the fourth quarter. Penserra Capital Management LLC now owns 1,210 shares of the company’s stock worth $169,000 after buying an additional 794 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC grew its position in Allakos by 71.2% during the first quarter. O Shaughnessy Asset Management LLC now owns 1,515 shares of the company’s stock worth $174,000 after buying an additional 630 shares in the last quarter. Institutional investors own 72.92% of the company’s stock.
ALLK has been the topic of several research reports. Zacks Investment Research lowered Allakos from a “hold” rating to a “sell” rating in a research note on Friday, May 14th. HC Wainwright initiated coverage on Allakos in a research note on Tuesday, May 18th. They issued a “buy” rating and a $230.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on Allakos in a research note on Wednesday, February 24th. They issued an “overweight” rating and a $218.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $183.25.
Allakos Inc operates as a clinical stage biopharmaceutical company. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis.
See Also: Quiet Period Expirations
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Market Capitalization – What it Means for Investors
By the time you read this Vladimir Tenev, the CEO of the trading app Robinhood, will be testifying in front of Congress. The company’s role in the GameStop (NYSE:GME) short squeeze will be called into question.
However, the real issue at stake is the right of traders to buy and sell the equities of their choice. In the case of Robinhood, some traders are buying a lot of penny stocks. While definitions vary, penny stocks are generally considered stocks that are trading for less than $10 per share. These stocks are largely ignored by the investment community.
One reason is that many of these stocks are cheap for a reason. For example, the company may have a business model that is out of date. In other cases, they operate in a very small, niche market that doesn’t drive a lot of revenue.
And most of these stocks are ignored by the investment community. They simply aren’t considered significant enough to spend time debating.
But some penny stocks do have the attention of Wall Street. And they’re being largely ignored by the day trading community. The focus of this special presentation is to direct you to penny stocks that have a story that the “smart money” thinks will eventually be trading at much higher prices.
And that’s why you should be looking at them now.